证券代码：300497 证券简称：富祥药业 公告编号：2025-049 江西富祥药业股份有限公司 独立董事候选人声明与承诺 声明人 刘洪 作为江西富祥药业股份有限公司第五届董事会独立董事候选人， 已充分了解并同意由提名人 江西富祥药业股份有限公司董事会 提名为江西富祥药 业股份有限公司（以下简称该公司）第五届董事会独立董事候选人。现公开声明和 保证，本人与该公司之间不存在任何影响本人独立性的关系，且符合相关法律、行 政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任职 资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过江西富祥药业股份有限公司第五届董事会提名委员会资格审 查，提名人与本人不存在利害关系或者其他可能影响独立履职情形的密切关系。 √ 是 □ 否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所业 务规则规定的独立董事任职资格和条件。 √ 是 □ 否 如否，请详细说明：______________________________ 四、本人符合该公司章程规定的独立董事任职条 ...

证券代码：300497 证券简称：富祥药业 公告编号：2025-051 江西富祥药业股份有限公司 关于公司第一期员工持股计划存续期届满暨终止的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司（以下简称"公司"）于分别于2021年5月12日、2021 年5月28日召开第三届董事会第二十二次会议、第三届监事会第十六次会议和2021年 第一次临时股东大会，审议通过了《关于公司第一期员工持股计划（草案）及其摘要 的议案》《关于公司第一期员工持股计划管理办法的议案》等议案，同意公司实施第 一期员工持股计划（以下简称"本次员工持股计划"）。具体内容详见公司于巨潮资 讯网上披露的相关公告。 鉴于本次员工持股计划将于2025年6月28日存续期届满，根据中国证券监督管理 委员会《关于上市公司实施员工持股计划试点的指导意见》《深圳证券交易所上市公 司自律监管指引第2号——创业板上市公司规范运作》等相关规定，现将本次员工持 股计划的相关情况公告如下： 本次员工持股计划名下之日起算。 3、本次员工持股计划所获标的股票分三期解锁，解锁时点分别为自公司公告最 ...

证券代码：300497 证券简称：富祥药业 公告编号：2025-045 江西富祥药业股份有限公司 独立董事提名人声明与承诺 提名人 江西富祥药业股份有限公司董事会 现就提名 计小青女士 为江西富祥 药业股份有限公司第五届董事会独立董事候选人发表公开声明。被提名人已书面同 意作为江西富祥药业股份有限公司第五届董事会独立董事候选人（参见该独立董事 候选人声明）。本次提名是在充分了解被提名人职业、学历、职称、详细的工作经历、 全部兼职、有无重大失信等不良记录等情况后作出的，本提名人认为被提名人符合 相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董 事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过江西富祥药业股份有限公司第五届董事会提名委员会资 格审查，提名人与被提名人不存在利害关系或者其他可能影响独立履职情形的密切 关系。 √ 是 □ 否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得担 任公司董事的情形。 √ 是 □ 否 如否，请详细说明：___________ ...

江西富祥药业股份有限公司 章程修正案 鉴于公司将回购账户中 11,355,900 股用途由"用于实施员工持股计划或股权激励" 变更为"用于注销并减少注册资本"。本次股份注销和减资完成后，公司总股本减少 11,355,900 股，公司总股本将由 550,004,834 股变更为 538,648,934 股。注册资本由人 民币 550,004,834 元变更为人民币 538,648,934 元。同时，根据《公司法》《上市公司 章程指引》《上市公司信息披露管理办法》等有关法律法规及规范性文件的最新修订 和更新情况，公司修订《江西富祥药业股份有限公司章程》，其中公司拟调整三会结 构，将不再设置监事会，监事会的职权由公司董事会审计委员会行使。具体内容如下： 1、将《公司章程》中有关"股东大会"的表述统一修订为"股东会"； 2、删除《公司章程》第七章"监事会"的内容； 3、除上述调整外，《公司章程》其余修订具体如下： | 修订前 | 修订后 | | --- | --- | | 第六条 公司注册资本为人民币 | 第六条 公司注册资本为人民币 | | 550,004,834 元。 | 538,648,934 元。 | | | ...

一、被提名人已经通过江西富祥药业股份有限公司第五届董事会提名委员会资 格审查，提名人与被提名人不存在利害关系或者其他可能影响独立履职情形的密切 关系。 证券代码：300497 证券简称：富祥药业 公告编号：2025-046 江西富祥药业股份有限公司 独立董事提名人声明与承诺 提名人 江西富祥药业股份有限公司董事会 现就提名 刘洪先生 为江西富祥药 业股份有限公司第五届董事会独立董事候选人发表公开声明。被提名人已书面同意 作为江西富祥药业股份有限公司第五届董事会独立董事候选人（参见该独立董事候 选人声明）。本次提名是在充分了解被提名人职业、学历、职称、详细的工作经历、 全部兼职、有无重大失信等不良记录等情况后作出的，本提名人认为被提名人符合 相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董 事候选人任职资格及独立性的要求，具体声明并承诺如下事项： √ 是 □ 否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得担 任公司董事的情形。 √ 是 □ 否 如否，请详细说明：____________ ...

证券代码：300497 证券简称：富祥药业 公告编号：2025-038 江西富祥药业股份有限公司 关于变更回购股份用途并注销暨减少注册资本的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 三、本次变更回购股份用途的原因及后续安排 基于对公司未来发展的信心及价值的认可，公司综合考虑资本市场情况，为提高 公司长期投资价值并提升每股收益水平，进一步增强投资者信心，有效维护公司股价， 结合公司整体战略规划、库存股情况等因素，公司拟将回购账户中的11,355,900股用 途由"用于实施员工持股计划或股权激励"变更为"用于注销并减少注册资本"。 （www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》（公告编号：2021-045） 和《回购报告书》（公告编号：2021-055）。 公司于2022年6月30日披露了《关于回购公司股份实施完成暨股份变动的公告》 （公告编号：2022-077），截至2022年6月30日，公司通过股票回购专用证券账户以集 中竞价交易方式回购公司股份11,355,900股，占公司总股本的比例为2.06%，本次回购 公司股份的 ...

Financial Performance - In 2024, the company's operating revenue was 1.18 billion yuan, a decrease of 26.83% compared to 2023 [1] - The net profit attributable to shareholders was -272.10 million yuan, down 35.51% year-on-year [1] - The net profit after deducting non-recurring gains and losses was -304.53 million yuan, a decline of 54.12% from the previous year [1] - The basic earnings per share were -0.51 yuan, reflecting a 37.84% decrease compared to the previous year [1] Profitability Metrics - The gross margin for 2024 was 9.67%, a decrease of 0.96% year-on-year [2] - The net profit margin was -23.81%, down 9.94% from the previous year [2] Expense Management - Total operating expenses for 2024 were 257 million yuan, a reduction of 62.21 million yuan compared to the previous year [2] - The expense ratio increased to 21.80%, up 1.98% year-on-year [2] - Sales expenses decreased by 52.50%, management expenses decreased by 13.42%, and R&D expenses decreased by 23.39% [2] Employee Statistics - The total number of employees at the end of 2024 was 1,774, a decrease of 189 employees or 9.63% from the previous year [3][4] Executive Compensation - Total compensation for directors, supervisors, and senior management in 2024 amounted to 8.24 million yuan [6] - The highest-paid individual was the chairman and general manager, Bao Jianhua, who received 1.25 million yuan [6][7]

Market Overview - The Shanghai Composite Index is at 3343.05 points, slightly below the half-year line with a change of -0.11% [1] - The total trading volume of A-shares is 464.485 billion yuan [1] Stocks Above Half-Year Line - A total of 98 A-shares have surpassed the half-year line, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - *ST Tianshan: 13.33% deviation, closing price at 6.50 yuan, with a daily increase of 13.84% and turnover rate of 4.87% [1] - Xinghui Co., Ltd.: 10.53% deviation, closing price at 5.85 yuan, with a daily increase of 14.48% and turnover rate of 12.59% [1] - New Meixing: 9.82% deviation, closing price at 8.79 yuan, with a daily increase of 12.26% and turnover rate of 14.09% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Junshi Biosciences: 6.17% deviation, closing price at 30.73 yuan, with a daily increase of 6.96% [1] - Fuxiang Pharmaceutical: 5.24% deviation, closing price at 9.08 yuan, with a daily increase of 6.45% [1] - Jin Hong Group: 4.16% deviation, closing price at 9.08 yuan, with a daily increase of 10.06% [1] Summary of Deviation Rates - The report includes a detailed ranking of stocks based on their deviation rates from the half-year line, highlighting both high and low performers [1][2]

Core Viewpoint - Fuxiang Pharmaceutical plans to develop multiple plant-based meat products that closely mimic the texture and taste of real meat, leveraging new protein technology [1] Company Developments - The company aims to create over 10 consumer-oriented products through independent research and external collaborations [1] - Fuxiang has established the first domestic production line for microbial new protein with a capacity of 1,000 tons and is currently constructing a new line with an annual capacity of 20,000 tons [1] Industry Insights - According to Chen Jian, an academician from the Chinese Academy of Engineering, the production efficiency of new protein is 1,000 times higher than traditional livestock and fishery farming methods, with over 90% water savings and no need for pesticides or fertilizers [1] - The development of new protein can address key supply chain challenges in the meat, egg, and dairy industries, enhancing cost-effectiveness and sustainability, while also meeting national strategic needs for food security [1] - The industry has significant potential and market space for growth [1]

Group 1: Financial Performance and Market Trends - The company has seen a price decrease of 10-20% in key raw materials like 6-APA, which is expected to improve production costs for products like Shubatan and Tazobactam [2] - The company reported that the production cost of lithium battery electrolyte additives is now at an industry-leading level, although product prices remain low, resulting in lower profit margins [3] - The global market for Penem formulations is substantial and continues to grow, with some product prices showing an upward trend [3] Group 2: Product Development and Regulatory Approvals - The company has submitted the new food raw material registration for its microbial protein to the National Health Commission and received an acceptance notice, indicating progress towards market entry [3][11] - The company is actively expanding its production capacity in the microbial protein sector, with a current capacity of 1,200 tons per year and plans for a 20,000-ton project under construction [13] - The microbial protein market is projected to reach $290 billion by 2035, with a 22% market share for microbial fermentation protein, highlighting significant growth potential [10] Group 3: Strategic Focus and Future Outlook - The company is focusing on three main business segments: pharmaceutical manufacturing, lithium battery electrolyte additives, and synthetic microbial protein, aiming for sustainable growth [5][9] - The company anticipates that the increasing demand for alternative proteins driven by population growth will support the development of the microbial protein sector [10] - The management emphasizes that the pharmaceutical industry is a stable growth sector, with ongoing demand due to aging populations and increased health awareness [9][10] Group 4: Market Challenges and Investor Relations - The company acknowledges that its financial performance is influenced by market conditions, industry policies, and competition, which may lead to short-term volatility in stock prices [14][21] - The management is committed to improving operational efficiency and delivering better financial results to regain investor confidence [19][21] - The company is focused on maintaining transparency with investors regarding its financial health and future performance expectations [18][21]